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Upon infection with Schistosoma, antibody responses are mounted that are largely directed against
glycans. Over the last few years signiﬁcant progress has been made in characterising the antigenic prop-
erties of N-glycans of Schistosoma mansoni. Despite also being abundantly expressed by schistosomes,
much less is understood about O-glycans and antibody responses to these have not yet been systemati-
cally analysed. Antibody binding to schistosome glycans can be analysed efﬁciently and quantitatively
using glycan microarrays, but O-glycan array construction and exploration is lagging behind because
no universal O-glycanase is available, and release of O-glycans has been dependent on chemical methods.
Recently, a modiﬁed hydrazinolysis method has been developed that allows the release of O-glycans with
free reducing termini and limited degradation, and we applied this method to obtain O-glycans from
different S. mansoni life stages. Two-dimensional HPLC separation of 2-aminobenzoic acid-labelled O-
glycans generated 362 O-glycan-containing fractions that were printed on an epoxide-modiﬁed glass
slide, thereby generating the ﬁrst shotgun O-glycan microarray containing naturally occurring schisto-
some O-glycans. Monoclonal antibodies and mass spectrometry showed that the O-glycan microarray
contains well-known antigenic glycan motifs as well as numerous other, potentially novel, antibody
targets. Incubations of the microarrays with sera from Schistosoma-infected humans showed substantial
antibody responses to O-glycans in addition to those observed to the previously investigated N- and
glycosphingolipid glycans. This underlines the importance of the inclusion of these often schistosome-
speciﬁc O-glycans in glycan antigen studies and indicates that O-glycans contain novel antigenic motifs
that have potential for use in diagnostic methods and studies aiming at the discovery of vaccine targets.
 2015 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
).1. Introduction
Schistosomiasis (bilharzia) is a chronic and potentially deadly
parasitic disease. It is a major public health burden in (sub)tropical
areas with at least 230 million people being affected and many
more at risk of being infected with schistosomes (Gryseels et al.,
2006; Steinmann et al., 2006; Vos et al., 2012). Schistosomes have
a complex life-cycle with larval, adult worm and egg stages inter-
acting with the human host, each playing a role in immunology,
immunopathology and maintenance of infection. Although aschistosome infection can be treated effectively with
Praziquantel (Fenwick and Webster, 2006; Gray et al., 2011), this
does not prevent reinfection, emphasising the need for the devel-
opment of a prophylactic vaccine inducing protection against
schistosomiasis. Natural immunity to Schistosoma does occur, but
it takes many years of infection to develop, is gradually acquired
with age and involves several immunological parameters such as
T cell and speciﬁc antibody responses (Butterworth et al., 1988;
Khalife et al., 1989; Leenstra et al., 2006; Vereecken et al., 2007).
Antibody responses in schistosomiasis have mainly been stud-
ied using crude antigens or (recombinant) proteins. The majority
of antibodies generated during Schistosoma infection are, however,
directed against the highly abundant and immunogenic parasite
glycans (Eberl et al., 2001; Hokke and Deelder, 2001; Naus et al.,
2003b; Nyame et al., 2003; Hokke et al., 2007a,b; Kariuki et al.,
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toire (Nyame et al., 2004; Hokke and Yazdanbakhsh, 2005; Hokke
et al., 2007a). Elaborate studies on the glycome of the different
Schistosoma life stages have indicated that hundreds of different
glycan structures are present within the N- and O-linked glycans
and the glycosphingolipid glycans (GSL-glycans) (Hokke et al.,
2007a). Recently we showed, by shotgun glycan microarray, that
anti-glycan antibodies are induced against many N-linked and
GSL-glycans in schistosome-infected individuals and that the
shotgun glycan microarray is a valuable tool in deﬁning antigenic
glycans and glycan recognition proﬁles that can discriminate
groups within a serum cohort (Van Diepen et al., 2012a).
To date, schistosome-related glycan microarray studies have
mainly incorporated synthetic glycans, or N-glycans and GSL-
glycans that can be enzymatically derived from natural sources
(Van Diepen et al., 2012a; Mandalasi et al., 2013; McWilliam
et al., 2013; Luyai et al., 2014). Convenient methods to release
and recover intact reducing O-glycans such that they can be
reacted with a label or linker molecule and printed on a covalent
microarray are not yet available. However, O-glycans are highly
abundant in schistosome cercariae and eggs (Khoo et al., 1995,
1997; Huang et al., 2001; Jang-Lee et al., 2007) and antibody
responses to these glycans are likely to occur. Since some terminal
antigenic glycan elements are shared between different types of
glycans it is likely that subsets of anti-O-glycan antibodies will
be directed against antigenic glycan motifs that also occur as part
of N- or glycolipid glycans, but antibody responses to O-glycan-
speciﬁc motifs are also expected to be present. Unlike N-glycans,
biosynthesis of O-glycans occurs by sequential addition of single
glycosyl residues rather than via the initial transfer of a common
conserved lipid-linked precursor to the growing protein backbone.
As a consequence, O-glycans can display multiple core structures
(Brockhausen et al., 2009). For Schistosoma, three core structures
have been deﬁned to date (Khoo et al., 1997; Huang et al., 2001;
Jang-Lee et al., 2007). The majority of O-glycans expressed by
cercarial secretions contain the Galb1-3(Galb1-6)GalNAc core
(Schistosoma-speciﬁc) which can be modiﬁed by additional b1-
6Gal to Gal, but structures with Galb1-3(GlcNAcb1-6)GalNAc core
(mucin-type 2) have also been observed (Jang-Lee et al., 2007).
The cercarial glycocalyx has been shown to speciﬁcally carry com-
plex O-glycans with repeating units of unique multi-fucosylated -
3GalNAcb1-4GlcNAcb1-4Gala1- motifs (Khoo et al., 1995), but
the overall major terminal motifs expressed by cercarial O-glycans
are Galb1-4(Fuca1-3)GlcNAc (LeX) and tandem LeX (Jang-Lee et al.,
2007). In adult worms, O-glycans could not be directly detected by
MS (Wuhrer et al., 2006) but it has been shown previously by other
methods that adult worms excrete circulating cathodic antigen
(CCA) and circulating anodic antigen (CAA) that carry large O-
glycans with repeating LeX and GlcA-substituted GalNAc motifs,
respectively (Bergwerff et al., 1994; van Dam et al., 1994). The
egg-stage O-glycans are characterised by a multitude of different
terminal motifs. In contrast to cercariae and schistosomula, the
most predominant core motif is the mucin type-2 core and more
structures with higher masses are expressed. Similar to cercariae,
relatively high levels of LeX as well as (multi-)fucosylated
GalNAcb1-4GlcNAc (LDN) elements are expressed (Khoo et al.,
1997; Jang-Lee et al., 2007; Robijn et al., 2007).
In view of the unique core structures of schistosome O-glycans
and the expected occurrence of antigenic glycans motifs not pre-
sent in other glycan classes, we set out to develop a schistosome
shotgun O-glycan microarray. We applied a modiﬁed hydrazinoly-
sis method that allows the release of O-glycans with free reducing
termini in high yields with reduced levels of degradation products
(Kozak et al., 2012). O-glycans from cercariae, adult worms and
eggs were released, labelled with 2-aminobenzoic acid (2-AA)
and fractionated by two-dimensional HPLC. These were thenprinted on an epoxide-modiﬁed glass slide to generate the ﬁrst
Schistosoma O-glycan microarray. This new O-glycan array was
tested and compared with existing N- and GSL-glycan arrays using
anti-glycan monoclonal antibodies (mAbs) and infection sera,
revealing the occurrence of a number of antigenic O-glycans to
which substantial antibody responses are raised in schistosome
infection.
2. Materials and methods
2.1. Sera and ethics statement
Human sera were obtained from Schistosoma mansoni-infected
individuals living in the Piida community, Butiaba, which is situ-
ated on the shore of Lake Albert in Uganda where S. mansoni is
endemic. Ethical approval for the Piida study was obtained from
the Uganda National Council for Science and Technology (UNCST)
and cleared by the Ofﬁce of the President. The study was also sup-
ported by the Cambridge Local Research Ethics Committee, UK.
Prior to enrolment, the study was explained to each selected adult
or parent/guardian of each child selected for the study and verbal
consent was obtained. The study design, epidemiology and sample
collection have been described in detail previously (Naus et al.,
2003a). The child and adult sera used in this study were non-
randomly selected from the original Piida cohort study, matched
for infection intensity and balanced for sex as described previously
(Van Diepen et al., 2012a).
2.2. Materials
Mouse mAbs reactive to schistosome glycans were generated
from S. mansoni-infected mice and previously characterised by
screening against a small panel of synthetic neoglycoconjugates
(van Remoortere et al., 2000; Robijn et al., 2005). Included in the
present study were mAbs that bind to GalNAcb1-4GlcNAc
(LacdiNAc, LDN, mAb 273-3F2), GalNAcb1-4(Fuca1-3)GlcNAc
(LDN-F, mAb 114-4E8-A), Fuca1-3GalNAcb1-4GlcNAc, (F-LDN,
mAb 291-5D5), and Galb1-4(Fuca1-3)GlcNAc (Lewis X, LeX, mAb
291-4D10) (van Remoortere et al., 2000; Robijn et al., 2005;
Wuhrer et al., 2006).Schistosoma mansoni adult worms, cercariae
and eggs were obtained as reported previously (Robijn et al.,
2005). BSA- and NH2-linked synthetic oligosaccharide conjugates
were synthesised as previously described (Vermeer et al., 2000,
2003; van Roon et al., 2005; de Boer et al., 2007, 2008). Cy3 conju-
gated goat anti-human IgG (Fc-speciﬁc), BSA and ethanolamine
were from Sigma (Zwijndrecht, The Netherlands). Alexa Fluor
647 conjugated goat anti-human IgM (l chain speciﬁc), Alexa
Fluor 647 conjugated rabbit anti-mouse IgG (H+L), and Alexa
Fluor conjugated goat anti-mouse IgM (l chain speciﬁc) were from
Invitrogen (Breda, The Netherlands).
2.3. O-glycan release
O-glycans were released as described previously (Kozak et al.,
2012). Brieﬂy, S. mansoni adult worms, cercarial and egg protein
extracts were washed three times with 0.1% triﬂuoroacetic acid
(TFA) using centrifugal ﬁltration tubes with a molecular weight
cut-off of 10 kDa and dried down by vacuum centrifugation. The
O-glycans were released by addition of hydrazine and incubation
at 60 C for 6 h. Hydrazine was removed by centrifugal evaporation.
Samples were then placed on ice and re-N-acetylated by the addi-
tion of 200 ll of 0.1 M sodium bicarbonate and 21 ll of acetic anhy-
dride. Samples were vortexed and incubated on ice for 10 min. A
further aliquot of acetic anhydride (21 ll) was added to each sam-
ple, followed by vortexing and incubation at room temperature for
50 min. Released O-glycans were cleaned up by passing them
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and were dried by vacuum centrifugation prior to further use.
2.4. N-glycan and GSL-glycan release
N-glycans and GSL-glycans were released as described pre-
viously (Van Diepen et al., 2012a). Schistosoma mansoni male and
female worms, cercariae and eggs were homogenised in water
(4 ml per g wet weight) and methanol and chloroform were added
sequentially (7 and 13 volumes, respectively). The upper phase
contained the GSL and the pellet the (glyco)proteins. Glycans were
released from the different preparations of S. mansoni glycolipids
and glycoproteins by glycoceramidase and PNGase F treatment,
respectively.
2.5. Labelling and fractionation of released glycans
Released O-, N-, and GSL-glycans were labelled with 2-AA as
described previously (Ruhaak et al., 2010) and fractionated by
hydrophilic interaction liquid chromatography (HILIC) with ﬂuo-
rescence detection on a TSK gel Amide-80 column (4.6 mm inner
diameter (ID)  15.0 cm, particle size 3 lm, Tosoh Bioscience,
Germany). Eluent A consisted of 100% acetonitrile (ACN), Eluent
B consisted of 50 mM ammonium formate pH 4.4. A linear gradient
from 22.4% to 54.4% eluent B in 40 min was applied at a ﬂow rate
of 1 ml/min. Fluorescence detection was performed at kex–kem
360–425 nm. HILIC peak fractions were collected and dried by
centrifugal evaporation, and subsequently sub-fractionated in a
second dimension using reversed-phase (RP)-HPLC on a Superspher
100 RP-18 column (Merck Millipore, Germany). Eluent A consisted
of 0.1% formic acid; eluent B consisted of 95% ACN with 0.1% formic
acid. A linear gradient from 5% to 50% eluent B was applied at a
ﬂow rate of 200 ll/min. Fluorescence detection was performed at
kex–kem 360–425 nm and all peak fractions were collected.
2.6. Mass spectrometry
Glycan samples were analysed by MALDI-TOF-MS with
Ultraﬂex II and Ultraﬂextreme mass spectrometers (Bruker
Daltonics, Bremen, Germany) in the negative ion reﬂectron mode
using 2,5-dihydroxybenzoic acid (DHB, Bruker Daltonics)
(20 mg/ml in 30% ACN) as matrix. Glycopeakﬁnder (http://www.
glyco-peakﬁnder.org) was used as an aid to deﬁne glycan
compositions.
2.7. Glycan microarray construction
Glycan-containing HPLC fractions, (synthetic) glycoconjugates,
and (glyco)proteins were dissolved in 20 ll of 1 spotting buffer
(Nexterion Spot, Schott Nexterion, Germany) with 10% DMSO in
384-well small volume, deep well polypropylene plates (Greiner
Bio-One, Germany). Two types of arrays were printed, one
containing the N-glycans and GSL-glycans, and one containing
the O-glycans. For the N- and GSL-glycan array 389 samples (115
from adult worms, 127 from cercaria, 110 from eggs and 37 from
cercarial glycolipids) were printed. For the O-glycan array 362
samples (79 from adult worms, 137 from cercariae and 146 from
eggs), were printed. Both arrays also included synthetic
neoglycoconjugates (BSA-LeX, BSA-LDN, BSA-LDN-F, BSA-F-LDN,
BSA-F-LDN-F) as well as (glyco)protein extracts from S. mansoni
(adult worm antigen (AWA), TCA-precipitate of AWA (AWA-TCA),
soluble egg antigen (SEA), excretory/secretory (glyco)proteins from
eggs (ES), and cercarial antigen (CA)) as controls for binding of the
mAbs.
Glycan amounts were estimated based on peak height in the
HPLC and each sample was printed in triplicate at differentconcentrations (three-fold dilutions, starting from 10 lM or as
high as the sample amounts allowed) on epoxysilane-coated glass
slides (Slide E, Schott, Nexterion, Germany) by contact printing
using the Omnigrid 100 microarrayer (Genomic Solutions, Ann
Arbor, MI, USA) equipped with SMP3 pins with uptake channels
that deposit 0.7 nl at each contact. Each array was printed three
times on each glass slide. Dot spacing was 290 lm (X) and
245 lm (Y), and array spacing was 6000 lm. Printed slides were
incubated overnight at room temperature at sufﬁcient humidity
to prevent drying of the spots and to allow covalent binding of
printed 2-AA labelled glycans and glycoconjugates to the epoxysi-
lane coating via reaction with primary or secondary amines (de
Boer et al., 2007).
2.8. Binding assay
Microarray slides were covered with a hand-cut silicone gasket
creating barriers to separate the three printed arrays and to keep
wash and incubation solutions within the individual array areas.
To remove unbound compounds, the arrays were rinsed with
1 ml of PBS. Remaining active epoxysilane groups were blocked
with 2% BSA, 50 mM ethanolamine in PBS for 60 min at room tem-
perature while shaking. Subsequently, the slides were rinsed with
PBS. Each microarray was incubated with mAb or serum diluted in
PBS-0.01% Tween20 with 1% BSA (mAbs diluted 1:200 or 1:1000;
serum diluted 1:100) for 60 min at room temperature while shak-
ing. After washing with successive rinses of PBS-0.05% Tween20
and PBS, the slides were incubated with ﬂuorescently labelled
anti-IgG and/or anti-IgM (diluted 1:1000 in PBS-0.01 Tween20)
for 30 min at room temperature while shaking and protected from
exposure to light. After a ﬁnal rinse with PBS-0.05% Tween20, PBS
and water, the slides were dried and kept in the dark until
scanning.
2.9. Scanning and data analysis
A G2565BA scanner (Agilent Technologies, Santa Clara, CA, USA)
was used to scan the slides for ﬂuorescence at 10 lm resolution
using two lasers (532 nm and 633 nm). At these wavelengths the
2-AA label does not ﬂuoresce. Data and image analysis were per-
formed with GenePix Pro 7.0 software (Molecular Devices,
Sunnyvale, CA, USA). Spots were aligned and re-sized using round
features with no composite pixel intensity (CPI) threshold.
Background-subtracted median intensities were averaged and pro-
cessed as described previously (Oyelaran et al., 2009; Van Diepen
et al., 2012a) and median values of negative controls included on
each array were subtracted.3. Results
3.1. Generation of a shotgun O-glycan microarray
O-glycans were obtained from different life stages (cercariae,
adult worms and eggs) of S. mansoni by hydrazinolysis, labelled
with 2-AA and puriﬁed. These samples were analysed by MALDI-
TOF-MS to determine their glycan contents. A broad range of O-
glycan compositions were present in the cercarial- and egg-derived
samples and, although there was some overlap in compositions,
the majority of compositions and proposed structures differed
between these sources. (Fig. 1A, C; Table 1). These samples were
fractionated by HILIC and a total number of 23 cercarial and 36
egg fractions were collected (Fig. 1B, D). For the adult worm-
derived O-glycan sample, no glycans could be detected by
MALDI-TOF-MS but the HILIC proﬁle showed 28 low intensity
peaks that were collected as fractions (data not shown). For all
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Fig. 1. Negative-ion MALDI-TOF-MS spectra (A, C) and hydrophilic interaction liquid chromatography chromatograms with ﬂuorescence detection (B, D) of Schistosoma
mansoni cercarial- (A, B) and egg-derived (C, D) 2-aminobenzoic acid-labelled O-glycan pools. All MALDI-TOF-MS signals are labelled with monoisotopic masses, structures
are shown for peaks with signal/noise higher than 10 and are based on data from the literature (Khoo et al., 1995; Huang et al., 2001; Jang-Lee et al., 2007) and our
unpublished MS/MS data. HILIC chromatograms with numbers indicating the fractions that were collected. Blue square, N-acetylglucosamine; yellow square, N-
acetylgalactosamine; yellow circle, galactose; red triangle, fucose. The asterisk indicates a 2-aminobenzoic acid-labelled peeling product. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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ated in a second dimension using RP-HPLC. All collected RP frac-
tions were then analysed by MALDI-TOF-MS. Glycans were
detected in 114 cercarial, 50 adult worm, and 110 egg RP-HPLC
fractions with a total number of 178, 46 and 170 different glycan
compositions, respectively. The adult worm-derived fractions con-
tained only very low amounts of O-glycans based on peak heights
in HPLC and in MALDI-TOF-MS. Only the fractions containing gly-
cans identiﬁed by MS were used to generate O-glycan microarrays.
These arrays were probed with anti-glycan mAbs and human sera
to uncover antigenic O-glycan structures. For comparison, we used
the previously generated shotgun glycan microarray containing N-
glycans and lipid glycans derived from S. mansoni cercariae, adult
worms and eggs (Van Diepen et al., 2012a).
3.2. mAb binding
To test the functionality of the array, we used four anti-glycan
mAbs reactive with glycan structures expressed by different life
stages of S. mansoni as previously determined by immunoﬂuores-
cence microscopy (Table 2), and analysed these on the new shot-
gun O-glycan microarray as well as the previously generated
shotgun N- and GSL-glycan microarray for comparison. For all
mAbs tested, the binding to crude aqueous extracts of adult
worms, cercariae and eggs was analysed and glycan speciﬁcity
was conﬁrmed by binding to synthetic conjugate controls printed
on the arrays (Table 2).mAb 291-4D10-A (anti-LeX) bound to gly-
cans expressed by worms (gut, parenchyma and tegument) and
eggs (shell and excreted antigen), while for cercariae only the oral
sucker was stained in the immunoﬂuorescence assay (Table 2).
Hardly any binding to cercarial-derived O-glycans was observed,
while responses against egg-derived O-glycans were very high,especially for the more complex O-glycans originating from late
HILIC fractions (Fig. 2A). This indicates that many of the egg-
derived O-glycans contain LeX elements to which the antibody
bound, while this was much less for the cercarial-derived
O-glycans. With respect to the N-glycan microarray, we observed
binding to many of the cercarial GSL-glycans and to only a few
worm, cercarial and egg N-glycans (Fig. 2A).
The mAbs 273-3F2 (anti-LDN) and 114-4E8 (anti-LDN-F) both
bound to structures expressed by worms (parenchyma and
tegument) and eggs (shell and miracidia), while binding to cer-
cariae was lacking (Table 2). In addition, 114-4E8 showed binding
to structures expressed in the worm gut, whereas 273-3F2 bound
to excreted egg antigen. The mAb 273-3F2 showed no binding to
any of the O-glycans printed, indicating that none of those con-
tained the non-substituted LDN element, relative abundance of
LDN was too low to be detected by the antibody, or the antibody
only binds to LDN in a speciﬁc structural context (Fig. 2B). mAb
114-4E8, on the other hand, did show binding to some of the
egg O-glycans but binding to cercarial O-glycans was virtually
absent (Fig. 2C). This shows that some of the egg O-glycans con-
tain LDN-F, while cercarial O-glycans do not. In addition to egg
glycolipids, mainly egg glycoproteins expressing LDN-F have pre-
viously been shown to be the major targets of this mAb on IFA
and Western blots (Nyame et al., 2003; Robijn et al., 2005). The
major difference between the two antibodies is that 114-4E8
showed binding to egg O- and N-glycans while 273-3F2 only
bound N-glycans (Fig. 2B, C). The binding properties of mAb 273-
3F2 have not been described before, but Nyame et al. (2003)
described another anti-LDN antibody and showed that it bound
more abundantly to egg glycoproteins than to glycoproteins from
cercariae (Nyame et al., 2003). Also the anti-LDN antibody that
was used in our study showed binding to egg-derived N-glycans
Table 1
Glycan masses and compositions in released O-glycan pools from different life stages of Schistosoma mansoni.
Registered m/za Glycan compositionb Corec Proposed glycan motifsd Registered m/za Glycan compositionb Corec Proposed glycan motifsd
Cercarial-derived O-glycan pool
665.287 H2N1-AA II LN 1338.558 F1H4N2-AA III LeX, b1-6Gal, (F0-1)Gn
811.342 F1H2N1-AA V LeX 1347.603 F3H1N3-AA I LDN(F3), F1-3Gn
827.342 H3N1-AA III,V LN, b1-6Gal 1687.740 F2H4N3-AA II LeX, diLeX
852.370 F1H1N2-AA I FGn 1696.784 F4H1N4-AA I LDN(F1-4), (F0-3)Gn
868.371 H2N2-AA I,II LN, Gn 1712.782 F3H2N4-AA IV LDN(F0-3)
973.408 F1H3N1-AA V LeX, b1-6Gal 1842.844 H3N6-AA IV LDN
998.452 F2H1N2-AA I F2Gn F5H1N4-AA I LDN(F2-5), (F0-3)Gn
1014.439 F1H2N2-AA I,II LeX, FGn 1858.837 F4H2N4-AA I LDN(F1-4)
1030.433 H3N2-AA II LN 1988.920 F1H3N6-AA IV LDN(F0-1)
1055.477 F1H1N3-AA I LDN(F0-1), (F0-1)Gn F6H1N4-AA I LDN(F3-6), (F0-3)Gn
1144.514 F3H1N2-AA I F3Gn 2004.895 F5H2N4-AA IV LDN(F2-5)
1176.496 F1H3N2-AA II LeX 2061.949 F4H2N5-AA I Gal-LDN(F0-4), LDN(F0-4)
1192.496 H4N2-AA III LN, b1-6Gal, Gn 2150.972 F6H2N4-AA IV LDN(F3-6)
1201.537 F2H1N3-AA I LDN(F0-2), (F0-2)Gn 2208.012 F5H2N5-AA I Gal-LDN(F0-5), LDN(F0-5)
Egg-derived O-glycan pool
665.328 H2N1-AA II LN 1493.755 F4H1N3-AA I LDN(F4), (F2)Gn
811.401 F1H2N1-AA V LeX 1525.742 F2H3N3-AA I,II LeX, di-LeX, FGn
852.435 F1H1N2-AA I FGn 1550.778 F3H1N4-AA I LDN(F0-3), (F0-2)Gn
868.426 H2N2-AA I,II LN, Gn 1566.770 F2H2N4-AA I Gal-LDN(F0-2), (F0-2)Gn
909.449 H1N3-AA I LDN, Gn 1582.775 F1H3N4-AA I,II LeX, (F)Gn, LN
998.504 F2H1N2-AA I F2Gn 1607.806 F2H1N5-AA I LDN(F0-2)
1014.498 F1H2N2-AA I,II LeX, FGn 1623.811 F1H2N5-AA I Gal-LDN(F0-1), LDN(F0-1)
1055.529 F1H1N3-AA I LDN(F0-1), (F0-1)Gn 1639.816 H3N5-AA I Gal-LDN
1071.526 H2N3-AA I,II Gal-LDN, Gn F5H1N3-AA I LDN(F5)
1112.552 H1N4-AA I LDN, Gn 1712.862 F3H2N4-AA I Gal-LDN(F0-3), (F0-2)Gn
1160.568 F2H2N2-AA V Gal-LDN(F2) 1728.852 F2H3N4-AA I,II LeX, diLeX, (F)Gn, LN
1176.562 F1H3N2-AA II LeX 1744.844 F1H4N4-AA I,II LeX, LN, (F)Gn
1201.600 F2H1N3-AA I LDN(F2), (F0-2)Gn 1753.889 F3H1N5-AA I LDN(F0-3)
1217.594 F1H2N3-AA I,II LeX, LN, (F0-1)Gn 1769.886 F2H2N5-AA I Gal-LDN(F0-2), LDN(F0-2)
1233.596 H3N3-AA I,II LN, Gn 1785.900 F1H3N5-AA I Gal-LDN(F0-1)
1258.622 F1H1N4-AA I LDN(F0-1), (F0-1)Gn 1874.932 F3H3N4-AA I,II LeX, diLeX, FGn
1274.630 H2N4-AA I Gal-LDN, Gn 1890.934 F2H4N4-AA I,II LeX, diLeX, LN, (F)Gn
1290.647 F4H1N2-AA V LDN(F4) 1899.953 F4H1N5-AA I LDN(F0-4)
1315.660 H1N5-AA I LDN 1931.959 F2H3N5-AA I Gal-LDN(F0-2)
1322.641 F2H3N2-AA V diLeX 1973.019 F2H2N6-AA I LDN(F0-2), (F)Gn
1347.669 F3H1N3-AA I LDN(F3), (F0-3)Gn 1989.032 F1H3N6-AA I Gal-LDN(F0-1), (F)Gn
1363.673 F2H2N3-AA I,II LeX, FGn 2037.004 F3H4N4-AA I,II LeX, diLeX, tri-LeX, FGn
1379.671 F1H3N3-AA I,II LeX, LN, (F0-1)Gn 2078.045 F3H3N5-AA I Gal-LDN(F0-3)
1404.702 F2H1N4-AA I LDN(F0-2), (F0-2)Gn 2094.036 F2H4N5-AA I,II LeX, di-LeX, (F)Gn
1420.700 F1H2N4-AA I Gal-LDN(F0-1), (F0-1)Gn 2119.097 F3H2N6-AA I LDN(F0-3), (F0-2)Gn
1436.693 H3N4-AA I,II LN, Gn 2135.097 F2H3N6-AA I Gal-LDN(F0-2), (F0-2)Gn
1461.725 F1H1N5-AA I LDN(F0-1) 2240.139 F3H4N5-AA I LeX, di-LeX, LN, (F)Gn
1477.726 H2N5-AA I Gal-LDN, LDN 2484.282 F3H3N7-AA I Gal-LDN(F0-3), LDN(F0-3)
a Registered m/z for the given glycan composition when measured by MALDI in negative ion reﬂectron mode.
b F, Fucose; H, Hexose; N, N-acetyl-hexosamine, AA, 2-aminobenzoic acid.
c O-glycan core type; I, Galb1-3(GlcNAcb1-6)GalNAc (mucin-type) core; II, Galb1-3(Galb1-6)GalNAc (S. mansoni-speciﬁc) core; III, S. mansoni-speciﬁc core modiﬁed by
additional b1-6Gal to Gal; IV, -3GalNAcb1-4GlcNAcb1-3Gala1-motif (cercarial glycocalyx structure); V, peeling product.
d Putative glycan motifs are proposed on the basis of interpretation of the mass spectra aided by literature (Khoo et al., 1995; Huang et al., 2001; Jang-Lee et al., 2007) and
our unpublished MS/MS data; LeX, Galb1-4(Fuca1-3)GlcNAcb1-; LDN, GalNAcb1-4GlcNAcb1-; LDN-F, GalNAcb1-4(Fuca1-3)GlcNAcb1-; F-LDN, Fuca1-3GalNAcb1-
4GlcNAcb1-; F-LDN-F, Fuca1-3GalNAcb1-4(Fuca1-3)GlcNAcb1-.
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O-glycan fractions.
Anti-F-LDN(-F) mAb 291-5D5 binds to several glycoproteins
derived from cercariae and eggs as well as to glycolipids from cer-
cariae, adult worms and eggs (Robijn et al., 2005). It binds to the
excretory system of adult worms, egg shells and miracidia, and
to whole cercariae (Table 2). On the array, this mAb showed bind-
ing to almost all egg and cercarial O-glycan containing HPLC frac-
tions, indicating that many of the O-glycans contain F-LDN and/or
F-LDN-F (Fig. 2D). Strong binding was also observed to many of the
N- and GSL-glycans isolated from cercariae and eggs. Binding to
worm-derived O- and N-glycans was not observed (Fig. 2D).
Although this mAb has been described as an anti-F-LDN antibody,
it also binds to F-LDN-F (Table 2) so no clear distinction can be
made between structures expressing F-LDN and F-LDN-F elements
on the basis of mAb 291-5D5.3.3. Natural infection sera
The mAb binding indicates that the newly developed O-glycan
microarray is effective for the detection of anti-glycan antibodies
in a similarmanner to the N- and GSL-glycan array, and suggest that
speciﬁc, potentially different glycan epitopes are present on schisto-
some O-glycans. To further explore the microarray for discovering
antigenic O-glycans motifs, we analysed responses in natural schis-
tosome infections (Fig. 3). To this end we incubated the arrays with
pooled sera obtained from a heavily S. mansoni-infected population
in Uganda and compared responses from infected children
(<12 years of age, Fig. 3A, B) and adults (>20 years of age,
Fig. 3C, D). In these sera, large differences in responses to N- and
GSL-glycans have previously been described (Van Diepen et al.,
2012a) but antibody responses to O-glycans have not yet been stud-
ied. As shown previously, the overall IgG and IgM response patterns
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microarray were similar for children and adults, but with higher
ﬂuorescence intensities in children. However, the O-glycan
microarray showedmore pronounced differences between children
and adults, especially for IgG. Therewas amuch higher IgG response
against cercarial- and egg-derived O-glycans in children compared
with adults (Fig. 3A, C), especially to the complex high mass
O-glycans originating from later HILIC fractions. For IgM, the
response against egg andwormO-glycanswasmoderate in children
and absent in adults while the IgM response against cercarial O-gly-
cans was comparable between children and adults (Fig. 3B, D).3.4. Characterisation of differentially recognised O-glycans
To characterise some of the O-glycans to which serum antibod-
ies bound, we focused on the most pronounced antibody responses
(median ﬂuorescence intensity >20,000). Since we used pooled
sera, no statistical analysis could be applied to compare responses
between children and adults for individual glycan fractions.
Therefore, we applied a set of strict selection criteria to the dataset
to look for the most extreme differences. The criteria for selection
were such that the ratio of response between children and adults
was greater than 10 and the absolute difference in ﬂuorescence
intensity was at least 10,000. This resulted in seven differentially
recognised egg-derived and 18 cercarial-derived O-glycan fractions
for IgG (Table 3) and none for IgM. The glycan structures present in
these differentially recognised fractions were analysed by MALDI-
TOF-MS (Table 3 and Supplementary Table S1). Most of the
fractions contained mixtures of glycans, mainly due to variations
in fucose contents. For the differentially recognised cercariae-
derived O-glycans, the majority of glycan compositions have a
relatively high N-acetyl-hexosamine content with a variable num-
ber of fucose residues (indicating the presence of fucosylated
Galb1-4GalNAcb1-4GlcNAc or GalNAcb1-4GlcNAcb1-3Gal motifs
as previously described (Khoo et al., 1995; Jang-Lee et al., 2007)).
To conﬁrm this, we performed MALDI-TOF-MS/MS analysis on cer-
carial O-glycan fraction 15.6 which contained ﬁve related glycans
composed of identical H3N6 core structures but substituted with
different numbers of fucose residues. The fragmentation spectra
suggest that these glycans were composed of GalNAcb1-
4GlcNAcb1-3Gal repeats which showed clear differences in fucose
substitution patterns (Fig. 4). The glycan masses detected at m/z
2865.1 and 3157.2 [MH] were the most abundant (Fig. 4 total
spectrum), and the MS/MS analysis (Fig. 4C, E) indicated that both
contain the terminal Fuca1-2Fuca1-3GalNAc(Fuca1-2Fuca1-
2Fuca1-3)GlcNAc motif. We also showed that fucosylated H4N8
containing glycan fractions such as F10H4N8 in cercarial O-glycan
fraction 18.5 were composed of GalNAcb1-4GlcNAcb1-3Gal units
(Supplementary Fig. S1). Cercarial O-glycan fraction 15.1 contains
two types of glycan structures which are unique to schistosome
O-glycans. This fraction also contains H4N8 with up to four fucoses,
but its major component is F2H6N3 which can only be translated
into the S. mansoni-speciﬁc structure with a core GalNAc that has
two branches composed of Galb1-4(Fuca1-3)GlcNAcb1-3(Galb1-
6)Galb1. This glycan has been described as being found speciﬁcally
in cercarial O-glycans (Jang-Lee et al., 2007).
The majority of egg-derived O-glycan fractions that showed dif-
ferential binding of IgG in the children versus adults comparison
have a more equal share of N-acetyl-hexosamines and hexoses
which suggests the presence of O-glycans based on Gal-GlcNAc
or LeX repeats (Jang-Lee et al., 2007). Fraction 32.2 is a fraction
that contains glycans with different basic compositions. MALDI-
TOF-MS/MS analysis of each component indicated that most struc-
tures indeed contain LeX (Supplementary Fig. S1). In addition to
MS, incubation with deﬁned mAbs aided the annotation of the
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Fig. 2. Binding of monoclonal antibodies (mAbs) to O-glycans, N-glycans and glycosphingolipid-glycans isolated from different life stages of Schistosoma mansoni. Log2
background subtracted median ﬂuorescence intensities are shown for 291-4D10 (A, binds to LeX), 273-3F2 (B, binds to LDN), 114-4E8 (C, binds to LDN-F), and 291-5D5 (D,
binds to F-LDN(-F)). Aw, adult worms; cerc, cercariae; GSL, cercarial glycoshingolipid glycans.
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tions (Table 3).
4. Discussion
Over the last few years signiﬁcant progress has been made in
characterising the antigenic properties of N-glycans of S. mansoni
and other parasitic helminths. In contrast, much less is understood
about O-glycans and antibody responses to these have not yet been
systematically analysed. We have generated the ﬁrst known shot-
gun O-glycan microarray containing O-glycans isolated from
S. mansoni cercariae, adult worms and eggs, allowing the study of
antibody responses to naturally occurring O-glycans. Incubations
with natural infection sera showed highly abundant responses to
O-glycans, underlining the importance of the inclusion of these
often schistosome-speciﬁc O-glycans in glycan antigen studies.
As shown previously by glycan microarray analysis (Van Diepen
et al., 2012a), IgG and IgM responses to N-glycans and GSL-glycans
were higher in schistosome-infected children compared with
adults (Fig. 2) in a Ugandan population. Since these child and adult
pools were matched for infection intensity and balanced for sex,
these results are likely due to a phenomenon that reﬂects human
host age or duration of infection in schistosomiasis-endemic areas.
Using the new O-glycan microarray, more pronounced differences
were observed between the children and adult groups. In particu-
lar, IgG responses against relatively large and more complex cer-
carial and egg-derived O-glycans were higher in children. Similar
to IgM responses against N-glycans and GSL-glycans, the IgM
response against egg-derived O-glycans was higher in children that
in adults. However, the response against cercarial-derived O-gly-
cans was found to be comparable between children and adults,both with respect to ﬂuorescence intensity and to glycan targets
bound. This is an interesting observation which warrants further
research to determine what causes the relatively high and speciﬁc
anti-cercarial O-glycan IgM responses in the adult group, while
anti-egg O-glycan responses were decreased similar to all of the
other anti-glycan responses in the adult group. One possible expla-
nation is that while adults in general decrease overall antibody
responses to schistosome glycans, exposure to new invading cer-
cariae still leads to the induction of strong antibody responses to
those O-glycans that are unique to those larvae. These observations
in any case illustrate that schistosome O-glycans contain antigenic
glycan motifs that are a relevant addition to those present on
N-glycans and GSL-glycans.
During the process of isolation and fractionation of O-glycans
for construction of the shotgun O-glycan microarray, we were able
to characterise a large set of O-glycans expressed by S. mansoni
using MALDI-TOF-MS. The O-glycosylation proﬁles of eggs and cer-
cariae were found to be largely in line with those reported by Jang-
Lee et al. (2007) and showed life stage-speciﬁc glycan com-
positions as well as shared glycan elements. The majority of cercar-
ial O-glycans contain a Galb1-3(Galb1-6)GalNAc (Schistosoma-
speciﬁc) core which can be modiﬁed by additional b1-6Gal residue,
while the Galb1-3(GlcNAcb1-6)GalNAc (mucin type-2) core is the
most predominant in egg-derived O-glycans (Khoo et al., 1997;
Jang-Lee et al., 2007). The modiﬁed hydrazinolysis method that
we used allows the release of O-glycans with free reducing termini
in high yields with reduced levels of degradation products (Kozak
et al., 2012). Indeed, we were able to isolate many different intact
O-glycans in amounts which allowed the construction of a
microarray by which antibodies to O-glycans could be sensitively
detected. In some of the selected cercarial O-glycan containing
A B
DC
Fig. 3. Binding of serum antibodies from Schistosoma mansoni-infected children <12 years (A, B) and adults >20 years of age (C, D) to glycans from different life stages of S.
mansoni. Average background subtracted median ﬂuorescence intensities are shown for IgG (A, C) and IgM (B, D). Aw, adult worms; cerc, cercariae; GSL, cercarial
glycoshingolipid glycans.
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H4N8 with different degrees of fucosylation (Table 3). MALDI-
TOF-MS/MS revealed linear structures, as shown in Fig. 4 and
Supplementary Fig. S1, which appeared to be peeling products of
large glycocalyx O-glycans, reﬂecting only one branch of the origi-
nal structure (Khoo et al., 1995). Such degradation products were
previously unexpectedly observed during conventional hydrazi-
nolysis release of core-2 based multifucosylated LDN containing
schistosome egg O-glycans (Robijn et al., 2007). Apparently
glycocalyx-derived O-glycans are very sensitive to partial degrada-
tion, even during the modiﬁed hydrazinolysis procedure applied
(Kozak et al., 2012). This partial degradation still allowed 2-AA-
reaction of the reducing end monosaccharide and did not limit
the goal of our study. The antigenic glycan elements present within
the linear branch derived from the degraded branched core glycan
are intact and strong antibody responses were observed (Fig. 3;
Table 3). In addition to MS, incubation with deﬁned mAbs enabled
us to increase our knowledge of the glycan elements and glycan
structures in the fractions printed on the O-glycan array
(Table 3). This is a vital step towards a better understanding of
the speciﬁcity of the anti-glycan antibodies induced by infection
with schistosomes. Due to the extreme complexity of the schisto-
some O-glycome, even a two-dimensional HPLC separation of
O-glycans did not result in a complete separation of all glycans
present. However, the array does allow the deﬁnition of a number
of antigenic motifs that were not previously identiﬁed. An exten-
sive list of glycan compositions was composed for both egg and
cercarial O-glycans through MALDI-TOF-MS analysis and mAb
incubations (Tables 1 and 3), but we were unable to detect any gly-
can compositions in the O-glycans released from adult worms. This
is in line with an earlier study in which no O-glycans were detected
in a chemically released glycan pool obtained from adult worms(Wuhrer et al., 2006). A possible explanation for the absence of
detectable O-glycans in these adult worm glycan pools is that they
may be present in amounts that are too low to be measured with-
out further concentration and puriﬁcation. The well-described gut-
associated antigens, CCA and CAA, that carry long polymeric
O-linked carbohydrates chains, were also not detected (Bergwerff
et al., 1994; van Dam et al., 1994). After fractionation by HILIC
and RP-HPLC we were able to detect a few O-glycans, albeit only
in very small amounts which suggests that, besides expression
on CAA and CCA, O-linked glycosylation is limited on S. mansoni
adult worm glycoproteins. In four of the isolated RP-HPLC fractions
we were able to detect glycan masses corresponding to structures
containing three hexuronic acid (HexA) and three HexNAc residues
(HexA3HexNAc3-AA) which is a composition that is characteristic
for CAA which carry glucuronic acid-substituted GalNAc polymers
(Bergwerff et al., 1994).
In addition to providing structural information on O-glycans on
the array, incubations with mAbs also revealed more detailed
glycan speciﬁcity of the mAbs and consequently about the glycans
visualised in IFA at the surface of the different schistosome life
stages (Table 2). For instance mAb 291-4D10-A, which has speci-
ﬁcity for synthetic LeX, showed binding to SEA and O-glycans
derived from SEA but not to CA nor to the majority of cercarial
O- and N-glycans. LeX is, however, expressed by cercarial N- and
O-glycans (Huang et al., 2001; Khoo et al., 2001; Jang-Lee et al.,
2007; Van Diepen et al., 2012b), but either the relative expression
levels are insigniﬁcant in the released glycan sample due to rela-
tively high abundance of fucosylated GalNAcb1-4GlcNAcb1-3Gal
variants in the cercarial O-glycan fractions (Fig. 4) and therefore
less fractions contain LeX, or the mAb has a speciﬁcity for a par-
ticular structural context of LeX that is associated with the egg
but not the cercarial glycans. Possibly, binding of the mAb to the
Table 3
Differential IgG responses to O-glycans in children <12 years of age and adults >20 years.
MFIa Monoclonal antibody bindingb Glycans present in fraction
Children Adults 291-4D10 (LeX) 273-3F2 (LDN) 114-4E8 (LDN-F) 291-5D5 (F-LDN(-F)) Compositionc Cored Proposed glycan motif(s)e
32.2 SEA 40,359 3366 +++  + +++ F2-3H4N4 I,II LeX, di-LeX, tri-LeX, LN, (F)Gn
F3H5N4 II LeX, di-LeX, tri-LeX
F3-4H3N5 I Gal-LDN(F0-4)
F2-4H4N5 I,II LeX, di-LeX, tri-LeX, (F)Gn
32.4 SEA 22,962 1096 +++  ++ ++ F2-3H4N4 I,II LeX, di-LeX, tri-LeX, LN, (F)Gn
H9N2 V Mannose
F2-4H3N5 I Gal-LDN(F0-4)
33.3 SEA 22,315 2133 ++ +/ + ++ F2-4H4N5 I,II LeX, di-LeX, tri-LeX, (F)Gn
F2-4H3N6 I Gal-LDN(F0-4), (F)Gn
34 SEA 22,841 2194 ++  + ++ F3-4H5N4 II LeX, di-LeX, tri-LeX
F2-4H4N6 I (F)Gn
F3-4H3N7 I Gal-LDN(03-4), LDN(F0-4), (F)Gn
36.2 SEA 34,861 3303 +++  + ++ F3-4H5N5 I,II LeX, di-LeX, tri-LeX, LN, (F)Gn
F4H4N6 I (F)Gn
F4-5H5N6 I,II LeX, di-LeX, tri-LeX, (F)Gn
F4-5H6N5 II LeX, di-LeX, tri-LeX
36.3 SEA 39,196 3364 +++  ++ +++ F3-4H4N6 I (F)Gn
F4H5N5 I,II LeX, di-LeX, tri-LeX, (F)Gn
F3-5H5N6 I,II LeX, di-LeX, tri-LeX, (F)Gn
F3-5H4N7 I Gal-LDN(F0-5)
36.5 SEA 48,911 3928 +++ +/ ++ +++ F4H4N6 I (F)Gn
F4H5N5 I,II LeX, di-LeX, tri-LeX, (F)Gn
10.6 CA 44,023 3682    +++ F2-5H1N4 I LDN(F0-5), F0-3Gn
F0-2H4N3 II LeX, di-LeX, LN
10.10 CA 50,204 3649    ++ H6N2 V Mannose
F1-6H2N4 IV LDN(F0-6)
F1-6H2N5 I LDN(F0-6), Gal-LDN(F0-5)
11.5 CA 56,047 5251    +++ F2-7H2N4 IV LDN(F1-6)
12.7 CA 37,977 2057    ++ F5-8H2N5 I LDN(F0-6), Gal-LDN(F0-5)
12.8 CA 28,324 2031    ++ H7N2 V mannose
H8N2 V mannose
13.4 CA 31,722 2218    + F1,2,4H4N8 IV LDN(F0-4)
14 CA 42,474 2478    ++ F2H5N3 III LeX, FGn
F3H5N4 II,III LeX, di-LeX, tri-LeX, FGn
15.1 CA 21,256 1898    ++ F1-2H6N3 III LeX, LN
F0-4H4N8 IV LDN(F0-4)
15.2 CA 39,693 2962    ++ F0-5H4N8 IV LDN(F0-5)
F2H6N3 III LeX
F1-2H6N4 II,III LeX, di-LeX, LN, (F)Gn
F4-7,9H3N7 I LDN(F0-5), Gal-LDN(F0-5)
15.5 CA 38,916 2465    +++ F2-8H3N6 IV LDN(F0-6)
F2,4H4N8 IV LDN(F0-4)
15.6 CA 53,281 3961    ++ F5-9H3N6 IV LDN(F0-6)
15.8 CA 44,816 3124    ++ H9N2 V mannose
F4-6H3N7 I LDN(F0-6), Gal-LDN(F0-5)
17.3 CA 41,735 3941 +/   ++ F2H7N4 II LeX, di-LeX, LN
18.5 CA 47,495 3439    + F6-12H4N8 I LDN(F0-6)
20.2 CA 36,878 2781    ++ F4-6H2N5 I LDN(F0-6), Gal-LDN(F0-5)
21 CA 50,473 4510    ++ nd  
22 CA 31,962 3094    ++ nd  
SEA, soluble egg antigen; CA, cercarial antigen.
a MFI, median ﬂuorescence intensity.
b Binding intensity factor compared with background signal (-, no binding; +/, factor >2; +, factor >5 ++, factor >25; +++, factor >100).
c F, Fucose; H, Hexose; N, N-acetyl-hexosamine.
d O-glycan core type; I, Galb1-3(GlcNAcb1-6)GalNAc (mucin-type) core; II, Galb1-3(Galb1-6)GalNAc (Schistosoma mansoni-speciﬁc) core; III, S. mansoni-speciﬁc core
modiﬁed by additional b1-6Gal to Gal; IV, -3GalNAcb1-4GlcNAcb1-3Gala1-motif (cercarial glycocalyx structure); V, N-glycan contaminant.
e Putative glycan motifs are proposed on the basis of interpretation of the mass spectra aided by literature (Khoo et al., 1995; Huang et al., 2001; Jang-Lee et al., 2007) and
our unpublished MS/MS data; LeX, Galb1-4(Fuca1-3)GlcNAcb1-; LDN, GalNAcb1-4GlcNAcb1-; LDN-F, GalNAcb1-4(Fuca1-3)GlcNAcb1-; F-LDN, Fuca1-3GalNAcb1-
4GlcNAcb1-; F-LDN-F, Fuca1-3GalNAcb1-4(Fuca1-3)GlcNAcb1-.
A. van Diepen et al. / International Journal for Parasitology 45 (2015) 465–475 473LeX element is hindered by expression of the Galb1-3(Galb1-
6)GalNAc core which is found in cercariae (Huang et al., 2001;
Jang-Lee et al., 2007). Binding was, however, observed against cer-
carial glycolipid glycans present on the N- and GSL-glycan array.
This is in line with a study by Robijn et al. (2005) where binding
of this antibody was mainly observed to cercarial glycolipid gly-
cans and egg glycoproteins. Since we observed hardly any binding
to egg-derived N-glycans but very abundant binding to egg-
derived O-glycans in our glycan microarray analysis we canconclude that this antibody, 291-4D10-A, mainly bound to egg
glycoproteins expressing O-linked glycans.
In conclusion, we have succeeded in generating the ﬁrst known
S. mansoni O-glycan microarray suitable for studying antibody
responses to a type of glycan which has to date been mostly
ignored. Incubations of mAbs and infection sera with the O-glycan
microarrays showed that O-glycans provide speciﬁc antigen tar-
gets. Antibodies to O-glycans in S. mansoni infection sera are abun-
dant and therefore likely play a role in immunity to Schistosoma.
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Fig. 4. MALDI-TOF-MS/MS spectra of glycans detected in Schistosoma mansoni cercarial antigen (CA) fraction 15.6 at m/z 2573.0 [MH] (A), 2719.0 [MH] (B), 2865.1
[MH] (C), 3011.1 [MH], and 3157.2 [MH] (E). Blue square, N-acetylglucosamine; yellow square, N-acetylgalactosamine; yellow circle, galactose; red triangle, fucose.
The percentage of each mass within cercarial antigen fraction 15.6 was calculated based on peak intensities in the MALDI-TOF analysis and is depicted in parentheses above
the structure. Y axis shows peak intensity (Intens.) in arbitrary units (a.u.). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
474 A. van Diepen et al. / International Journal for Parasitology 45 (2015) 465–475Further studies are necessary to understand how anti-O-glycan
antibodies are generated, both for those that cross-react with
N- and GSL-glycans and for those that are uniquely directed
against O-glycan motifs.
The isolation of N-glycans, O-glycans and GSL-glycans, and
the generation of a shotgun glycan microarray as described for
S. mansoni in this study, can be applied to all other helminth para-
sites that express antigenic glycans. When printed on a glass slide,
these glycans can now cover the full range of naturally occurring
protein- and lipid-linked glycans and glycan elements of each spe-
cies studied. Such glycan microarrays will be invaluable tools in
studies of anti-glycan antibody proﬁles and dynamics in human
and animal helminthiases. These studies will aid the search for gly-
can vaccine candidates and glycan antigens for diagnostic antibody
detection assays.Acknowledgements
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